Resistance to Lamivudine in HBV Egyptian Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01548820|
Recruitment Status : Completed
First Posted : March 8, 2012
Last Update Posted : September 10, 2013
|Condition or disease|
|Chronic Hepatitis B Virus Treatment|
Primarily: To study the correlations between the following parameters in adult Egyptian patients with chronic viral hepatitis B before treatment:
- HBV-DNA by quantitative PCR.
- Biopsy (if possible). Secondarily: After receiving lamivudine therapy we will identify the impact of these parameters on viral breakthrough at 1 year of therapy.
|Study Type :||Observational|
|Actual Enrollment :||230 participants|
|Official Title:||Pretreatment and On-treatment Indicators of Virologic Breakthrough in Chronic HBV Egyptian Patients Receiving Lamivudine Therapy|
|Study Start Date :||June 2010|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||January 2013|
Chronic HBV Egyptian patients
chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National Hepatology & Tropical Medicine Research Institute in Egypt.
- Resistance to Lamivudine Therapy [ Time Frame: 1 year ]Prevelance of Lamivudine resistance among HBV Egyptian cases pretreatment and on treatment parameters for Lamivudine therapy resistance
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01548820
|Tropical medicine department|